| 0 (0%) | 10-24 14:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.48 |
1-year : | 58.34 |
| Resists | First : | 40.65 |
Second : | 49.95 |
| Pivot price | 30.44  |
|||
| Supports | First : | 25.62 |
Second : | 21.31 |
| MAs | MA(5) : | 27.89 |
MA(20) : | 32.93 |
| MA(100) : | 32.9 |
MA(250) : | 23.74 |
|
| MACD | MACD : | -2.3 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 6.9 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 65.8 | Low : | 1.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VOR ] has closed above bottom band by 25.8%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.35 - 28.51 | 28.51 - 28.65 |
| Low: | 25.23 - 25.42 | 25.42 - 25.6 |
| Close: | 27.46 - 27.76 | 27.76 - 28.03 |
Wed, 22 Oct 2025
Major Stock Sale by Vor Biopharma Director Raises Eyebrows! - TipRanks
Wed, 22 Oct 2025
RA Capital funds sell $3.4m in Vor Biopharma (VOR) stock - Investing.com
Wed, 22 Oct 2025
Vor Bio to host webcast on telitacicept Phase 3 data in Sjögren’s - Investing.com
Wed, 22 Oct 2025
Vor Bio (NASDAQ: VOR) plans webcast on 48-week Phase 3 telitacicept data in Sjögren’s - Stock Titan
Wed, 22 Oct 2025
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease - GlobeNewswire
Tue, 21 Oct 2025
Major Shareholder Offloads Thousands of Vor Biopharma Shares! - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 32.6 (%) |
| Held by Institutions | 40.7 (%) |
| Shares Short | 1,350 (K) |
| Shares Short P.Month | 989 (K) |
| EPS | -273.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -239.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -121.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -48.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -150 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -0.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|